From the bridge – year-end message

From the bridge – year-end message
28 December 2023

If you are interested in the inner workings of Undervalued-Shares.com and my plans for next year, then read on to learn more about:

  • Why running real-life events is so useful for all readers.
  • What I set as my writing goals for 2024.
  • Which challenges I face operating Undervalued-Shares.com.

If you'd rather read about specific stocks, skip today's article and instead watch out for a very cool Weekly Dispatch tomorrow. It will cover a quirky sector!

2023: events, events, events

This past year saw me ramp up events with readers – finally!

Real-life meets and building a community had always been one of my top goals for Undervalued-Shares.com. After the pandemic, which had temporarily thrown a spanner in the works, 2023 offered a chance to deliver on the pent-up demand.

In May, 15 readers joined me on the investor trip to Turkey. Most of the Turkish companies we met only had vaguely interesting investment prospects, and trading Turkish stocks is near-impossible anyway. BUT the trip scored highly in terms of forging new friendships and professional contacts, and Istanbul proved a world-class location for such a get-together.

Event in Istanbul

In July, I hosted a dinner with investment legend Harris "Kuppy" Kupperman. With nearly 40 participants, we totally maxed out the London venue's capacity, and enjoyed a raucous evening with a thought-provoking talk.

In September, I hosted dinners with Michael Steindler, a highly successful German private investor turned fund manager. How did he achieve returns of >25% p.a. for 23 years, where does he turn to in order to generate ideas, and what are some of the themes he is looking at right now? Attendance was 34 in Munich, 24 in Frankfurt, 22 in Hamburg, 10 in London, and 14 in Guernsey. Needless to say, I was chuffed about the demand!

In October, I brought a dozen readers onto the investor trip to Hungary. Contrary to Turkey, this trip hit the mark in terms of interesting investments. Participants judged OTP Bank, ANY, and Raiffeisenbank International as their top finds of the trip. All three stocks are up strongly since then. As one participant emailed me: "ANY has already earned back the costs of the trip."

RBI Hungary

In November, I organised the US East Coast meet-ups as my first-ever reader gatherings across the pond. New York City and Washington, D.C. were quite intimate with half a dozen participants meeting in a bar. In Miami, I teamed up with the Explorer Partnership, hosting a dinner for 25.

Each of these events helped to generate interesting content for Undervalued-Shares.com, meaning they benefited not just those of my readers who were able to attend (check out "11 highlights from our dinner with Kuppy" as an example, or some of my recent research reports which include inputs from experts met at these real-life events). Clearly, the Undervalued-Shares.com community is getting bigger, stronger, and better with each year.

I have thoughts on how to improve these events further, and have started to develop a simple tool to help event participants build new professional contacts and friendships. Building new relationships is a key reason why readers come to these events. "I don't have anyone in my existing circle of friends with whom I can talk about these subjects" is something that participants said on countless occasions.

In any case, 2024 will see more such events and in other geographies, too.

Washington event

Research reports, articles, and other content

Earlier this year, the 250th Weekly Dispatch got published. I am just a bit proud that every Friday – come hell or high water – I put one of these free articles onto Undervalued-Shares.com.

"How on earth do you manage to write so much?" is a question that I often get asked.

Personally, I actually feel that my writing output is quite inadequate. There are so many subjects and ideas that I would love to write about, but which are stuck in a queue – a backlog of at least 50 articles and reports at any given time.

Yours truly at work in Puerto Rico

Yours truly at work in Puerto Rico.

Also, writing is never work for me but sheer pleasure. I love exploring new subjects and letting my readers come along for the ride.

My goals for 2024 include:

Can I get all of this done, you may wonder?

In 2024, I will become stricter about protecting my mornings – my most valuable writing time. Putting up barriers so that no one can eat into my morning hours should help me produce 10-20% more content across the year, as a minimum.

To get off to a good start, I have rented a house in the remote Galapagos Islands for all of February, where I will not have anyone mess with my focus before midday. Bliss! (In case you are passing through Santa Cruz Island that month, do let me know. We can have a coffee – in the afternoon!)

Gearing up but staying small

Undervalued-Shares.com is still very young (today is its 5th birthday!), and I do have the ambition to see it evolve and expand further. There are a few obvious missing aspects that would help you on your investment journey, and make this community grow further.

God willing, I intend to operate for a few more decades. I am in no hurry to rush through changes.

At the heart of Undervalued-Shares.com lies the idea that every single word was written by myself – and no one but myself.

That said, 2024 will generally see me lean more heavily on outsourcing tasks and hiring more staff. Heads-up, when you book event spaces next year, you'll probably hear from a colleague rather than myself.

Last but far from least, I'll also continue to lean on you – my dear readers – to help grow this operation. This past year, I have received INVALUABLE input from many of you, and in more ways than I can even keep track of:

  • Ideas and research.
  • Help with introductions and domain expertise.
  • Frank feedback and constructive criticism.

Thank you for being part of Undervalued-Shares.com in 2023, and I am sending you my best wishes for 2024.

Hot off the press: new in-depth research report

What do you call a publicly listed company where ALL large shareholders agree that the company should be sold?

A prime takeover target.

My latest research report – out this week exclusively for Lifetime Members – features one such target from the British Isles.

It is the market leader in its region, with a strong balance sheet and a valuable brand name.

A bid for this company will likely have to be at least 50-75% above the current share price.

In the crosshairs of private equity

Hot off the press: new in-depth research report

What do you call a publicly listed company where ALL large shareholders agree that the company should be sold?

A prime takeover target.

My latest research report – out this week exclusively for Lifetime Members – features one such target from the British Isles.

It is the market leader in its region, with a strong balance sheet and a valuable brand name.

A bid for this company will likely have to be at least 50-75% above the current share price.

In the crosshairs of private equity

Print this article

Did you find this article useful and enjoyable? If you want to read my next articles right when they come out, please sign up to my email list.

Share this post:

Subscribe to my news

  • Get your weekly dose of investment inspiration - and my FREE eBook "Weird Shit Investing 2024 - The Manual".
  • You can unsubscribe at any time. I'll treat your data with respect, see my Privacy Policy for details.
  • This field is for validation purposes and should be left unchanged.

Archive

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.